Category: Approval

September 30, 2015 Off

FDA approves Meiji’s QIDP and Fast Track Designation to ME1100

By Dino Mustafić

Meiji Seika Pharma Co., Ltd. announced on Tuesday that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, ME1100 (arbekacin inhalation solution), as a Qualified Infectious Disease Product (QIDP) for the adjunctive treatment of mechanically ventilated patients with bacterial pneumonia.